News
News release
-
Breaking Through Solid Tumors: UTC Therapeutics’ CAR-T Clinical Data to Be Presented at AACR 2026
Two pivotal CAR-T research programs were selected for presentation at AACR 2026. The company will unveil groundbreaking clinical data on a global first-in-human basis through one oral presentation and one poster presentation.
Details -
Good News Announcement! UTC Therapeutics awarded with the "Top Cancer Immunotherapy Solution In Asia 2025"
Lately, UTC Therapeutics has been honored with the "Top Cancer Immunotherapy Solution In Asia 2025" award by the renowned journal《Life Sciences Review.
Details -
The roots of UTC track back to UPenn, where our scien-tific founder Prof
ZHAO Yangbing was the director of T cell engineering lab, and co-founder Prof. LIU Xiaojun the deputy director. A pioneer in T cell therapy
Details -
The roots of UTC track back to UPenn, where our ...
ZHAO Yangbing was the director of T cell engineering lab, and co-founder Prof. LIU Xiaojun the deputy director. A pioneer in T cell therapy
Details -
Apart from involving in collab-oration with Novartis on the...
Is a bio-tech providing next-generation T-cell therapy to overcome TME challenges and it has raised over 200 million dollar from investors since
Details -
Founded in Octber of 2019 in Shanghai by ZHAO Yangbing
LIU Xiaojun, and SONG Xiaodong, an ex-Pfizer and ex-J&J executive, UTC therapeutics is a pre-clinical biotech focusing on adoptive
Details
